Effect of Recombinant Human EPO on the Postoperative Neurologic Outcome in Pediatric Moyamoya Patients
The Effect of Recombinant Human Erythropoietin on the Postoperative Neurologic Outcome in Pediatric Moyamoya Disease Patients - A Double Blind Randomized Controlled Trial
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Seoul, Korea, Republic of, 110-744
- Seoul National University Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Pediatric Moyamoya patients scheduled for the first revascularization surgery
Exclusion Criteria:
- Hypersensitivity or contraindication to rHuEPO
- History of Unstable hypertension, Hypertensive encephalopathy, Thrombosis
- Primary intracerebral hemorrhage (ICH), Subarachnoid hemorrhage (SAH), Arterio-venous malformation (AVM), Cerebral aneurysm, or cerebral neoplasm
- History of seizure
- Hemoglobin >16 mg/dl
- Prolonged PT (PT > 15.5 seconds, PT INR > 1.2) or Prolonged aPTT (> 40 seconds)
- Thrombocytopenia (platelet count < 100,000/microL), Thrombocytosis (platelet count > 400,000/microL), Neutropenia (absolute neutrophil count (ANC) < 1500/microL)
- Abnormal kidney function (Creatinine> 2.0 mg/dl, History of dialysis)
- Abnormal hepatic function (aspartate transaminase> 80 unit/L, alanine aminotransferase> 80 unit/L)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: rHuEPO
recombinant human erythropoietin 500 U/kg IVS x 3 times Preoperative day (12-24 hour before surgery) During surgery Postoperative day (12-24 hour after surgery)
|
Recombinant human erythropoietin (500 U/kg IVS x 3 times) is administrated to increase the neovascularization after revascularization surgery.
Other Names:
|
|
Placebo Comparator: Control
Normal saline 50mL x 3 times Preoperative day (12-24 hour before surgery) During surgery Postoperative day (12-24 hour after surgery)
|
Control group, no intervention.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
postoperative <12 month Angiogenesis
Time Frame: <12 month after revascularization operation
|
Incidence of Good postoperative MCA territory revascularization by cerebral angiography or MRI (3 grade: good, fair, poor)
|
<12 month after revascularization operation
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Short-term postoperative outcome: Incidence and number of the postoperative transient ischemic attack (TIA) within 1 week
Time Frame: up to 1 week
|
Incidence and number of the postoperative transient ischemic attack (TIA) within 1 week (yes or no)
|
up to 1 week
|
|
Short-term postoperative outcome: Adverse neurologic event
Time Frame: within the 1st postoperative hospital stay, up to 1 year
|
seizure, increased intracranial pressure, cerebral infarct, hematoma, reoperation (yes or no)
|
within the 1st postoperative hospital stay, up to 1 year
|
|
Short-term postoperative outcome: Other postoperative complications
Time Frame: within the 1st postoperative hospital stay, up to 1 year
|
e.g.
Circulatory failure/arrest, Respiratory failure/arrest, Infection (yes or no)
|
within the 1st postoperative hospital stay, up to 1 year
|
|
Short-term postoperative outcome: ICU stay (days)
Time Frame: within the 1st postoperative hospital stay, up to 1 year
|
ICU stay (discharge criteria: Stable V/S + Consciousness)
|
within the 1st postoperative hospital stay, up to 1 year
|
|
Short-term postoperative outcome: Total hospital stay (days)
Time Frame: within the 1st postoperative hospital stay, up to 1 year
|
Total hospital stay (discharge criteria: Stable V/S + no progressive Sx)
|
within the 1st postoperative hospital stay, up to 1 year
|
|
Effect of rHuEPO on perioperative erythropoiesis: Total intraoperative and perioperative transfusion requirements (mL/kg)
Time Frame: within the 1st postoperative hospital stay, up to 1 year
|
Total intraoperative and perioperative transfusion requirements (mL/kg)
|
within the 1st postoperative hospital stay, up to 1 year
|
|
Effect of rHuEPO on perioperative erythropoiesis: Perioperative Hemoglobin, Hematocrit, serum EPO level
Time Frame: within the 1st postoperative hospital stay, up to 1 year
|
Perioperative Hemoglobin, Hematocrit, serum EPO level
|
within the 1st postoperative hospital stay, up to 1 year
|
|
Effect of rHuEPO on perioperative erythropoiesis: GFR, BUN, Creatinine
Time Frame: within the 1st postoperative hospital stay, up to 1 year
|
GFR, BUN, Creatinine level
|
within the 1st postoperative hospital stay, up to 1 year
|
|
Postoperative <12 month neurologic outcome: Clinical outcomes (4 grade): Excellent, Good, Fair, Poor
Time Frame: Outpatient clinical visit, Usually Postoperative 3~6 month, up to 1 year
|
Clinical outcomes (4 grade): Excellent, Good, Fair, Poor
|
Outpatient clinical visit, Usually Postoperative 3~6 month, up to 1 year
|
|
Postoperative <12 month neurologic outcome: Brain Perfusion MRI (2 grade): Favorable, Unfavorable
Time Frame: Outpatient clinical visit, Usually Postoperative 3~6 month, up to 1 year
|
Brain Perfusion MRI (2 grade): Favorable, Unfavorable
|
Outpatient clinical visit, Usually Postoperative 3~6 month, up to 1 year
|
|
Long-term neurologic outcome: Clinical outcomes (4 grade): Excellent, Good, Fair, Poor
Time Frame: Outpatient clinical visit, Usually Postoperative 12~18 month, up to 2 years
|
Clinical outcomes (4 grade): Excellent, Good, Fair, Poor
|
Outpatient clinical visit, Usually Postoperative 12~18 month, up to 2 years
|
|
Long-term neurologic outcome: Brain MRI/A or Brain perfusion MRI
Time Frame: Outpatient clinical visit, Usually Postoperative 12~18 month, up to 2 years
|
Brain MRI/A or Brain perfusion MRI (2 grade): Favorable, Unfavorable
|
Outpatient clinical visit, Usually Postoperative 12~18 month, up to 2 years
|
|
Long-term neurologic outcome: Cognitive function assessed by Korean Wechsler Intelligence Scale for Children-Ⅳ (K-WISC-Ⅳ)
Time Frame: Outpatient clinical visit, Usually Postoperative 12~18 month, up to 2 years
|
Cognitive function assessed by Korean Wechsler Intelligence Scale for Children-Ⅳ (K-WISC-Ⅳ, has 4 domaines: Verbal Comprehension Index, Perceptual Reasoning Index, Working Memory Index, Processing Speed Index > final score is calculated from T-score)
|
Outpatient clinical visit, Usually Postoperative 12~18 month, up to 2 years
|
|
Preoperative Cerebral angiography: Suzuki grade, Bilateral involvement
Time Frame: Before up to 1 year
|
Cerebral angiography: Suzuki grade(1-6), Bilateral involvement (yes/no)
|
Before up to 1 year
|
|
Preoperative Brain MRI/A or Brain Perfusion MRI
Time Frame: If the preoperative w/u is not completed before recruitment, up to 1 week
|
Brain MRI/A or Brain Perfusion MRI (2 grade): Favorable, Unfavorable
|
If the preoperative w/u is not completed before recruitment, up to 1 week
|
|
Preoperative Hemoglobin, Hematocrit, serum EPO level
Time Frame: If the preoperative w/u is not completed before recruitment, up to 1 week
|
Preoperative Hemoglobin, Hematocrit, serum EPO level
|
If the preoperative w/u is not completed before recruitment, up to 1 week
|
|
Preoperative information: Homozygous RNF213
Time Frame: If the preoperative w/u is not completed before recruitment, up to 1 week
|
Homozygous RNF213
|
If the preoperative w/u is not completed before recruitment, up to 1 week
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
General Publications
- Yoo YC, Shim JK, Kim JC, Jo YY, Lee JH, Kwak YL. Effect of single recombinant human erythropoietin injection on transfusion requirements in preoperatively anemic patients undergoing valvular heart surgery. Anesthesiology. 2011 Nov;115(5):929-37. doi: 10.1097/ALN.0b013e318232004b.
- Hong JM, Lee SJ, Lee JS, Choi MH, Lee SE, Choi JW, Lim YC. Feasibility of Multiple Burr Hole With Erythropoietin in Acute Moyamoya Patients. Stroke. 2018 May;49(5):1290-1295. doi: 10.1161/STROKEAHA.117.020566. Epub 2018 Apr 6.
- Malla RR, Asimi R, Teli MA, Shaheen F, Bhat MA. Erythropoietin monotherapy in perinatal asphyxia with moderate to severe encephalopathy: a randomized placebo-controlled trial. J Perinatol. 2017 May;37(5):596-601. doi: 10.1038/jp.2017.17. Epub 2017 Mar 9.
- Kimakova P, Solar P, Solarova Z, Komel R, Debeljak N. Erythropoietin and Its Angiogenic Activity. Int J Mol Sci. 2017 Jul 13;18(7):1519. doi: 10.3390/ijms18071519.
- Aljaaly HA, Aldekhayel SA, Diaz-Abele J, Karunanayka M, Gilardino MS. Effect of Erythropoietin on Transfusion Requirements for Craniosynostosis Surgery in Children. J Craniofac Surg. 2017 Jul;28(5):1315-1319. doi: 10.1097/SCS.0000000000003717.
- Wu YW, Mathur AM, Chang T, McKinstry RC, Mulkey SB, Mayock DE, Van Meurs KP, Rogers EE, Gonzalez FF, Comstock BA, Juul SE, Msall ME, Bonifacio SL, Glass HC, Massaro AN, Dong L, Tan KW, Heagerty PJ, Ballard RA. High-Dose Erythropoietin and Hypothermia for Hypoxic-Ischemic Encephalopathy: A Phase II Trial. Pediatrics. 2016 Jun;137(6):e20160191. doi: 10.1542/peds.2016-0191. Epub 2016 May 2.
- Bang OY, Fujimura M, Kim SK. The Pathophysiology of Moyamoya Disease: An Update. J Stroke. 2016 Jan;18(1):12-20. doi: 10.5853/jos.2015.01760. Epub 2016 Jan 29.
- Kim T, Oh CW, Bang JS, Kim JE, Cho WS. Moyamoya Disease: Treatment and Outcomes. J Stroke. 2016 Jan;18(1):21-30. doi: 10.5853/jos.2015.01739. Epub 2016 Jan 29.
- Kim SK, Cho BK, Phi JH, Lee JY, Chae JH, Kim KJ, Hwang YS, Kim IO, Lee DS, Lee J, Wang KC. Pediatric moyamoya disease: An analysis of 410 consecutive cases. Ann Neurol. 2010 Jul;68(1):92-101. doi: 10.1002/ana.21981.
- Kim JH, Jung JH, Phi JH, Kang HS, Kim JE, Chae JH, Kim SJ, Kim YH, Kim YY, Cho BK, Wang KC, Kim SK. Decreased level and defective function of circulating endothelial progenitor cells in children with moyamoya disease. J Neurosci Res. 2010 Feb 15;88(3):510-8. doi: 10.1002/jnr.22228.
- Heeschen C, Aicher A, Lehmann R, Fichtlscherer S, Vasa M, Urbich C, Mildner-Rihm C, Martin H, Zeiher AM, Dimmeler S. Erythropoietin is a potent physiologic stimulus for endothelial progenitor cell mobilization. Blood. 2003 Aug 15;102(4):1340-6. doi: 10.1182/blood-2003-01-0223. Epub 2003 Apr 17. Erratum In: Blood. 2004 Jun 15;103(12):4388.
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- H-1812-165-999
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.